GlassScriptPhysician profile
Mary Beth Harr
NPI 1043372055
$9,723.60
in general payments reported to CMS, 2019-2025
49 companies · $998 in 2025
The $998 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,481 · 2020: $1,457 · 2021: $1,648 · 2022: $1,233 · 2023: $1,520 · 2024: $1,387 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,711 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,710.89 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,614.71 | 2021-2025 | |
| Lilly USA, LLC | $677.19 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Allergan, INC. | $587.80 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $547.02 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $541.28 | 2019-2025 | Trintellix |
| Amgen INC. | $469.42 | 2019-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $443.90 | 2019-2025 | |
| Amarin Pharma, INC. | $438.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $420.31 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $383.06 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $367.95 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $260.27 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $241.62 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $203.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $184.66 | 2019-2021 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.71 | 2020-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $174.17 | 2019-2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $147.01 | 2020-2023 | Nexletol |
| Merck Sharp & Dohme LLC | $145.73 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Paratek Pharmaceuticals, INC. | $141.43 | 2021-2023 | Nuzyra |
| Abbott Laboratories | $138.56 | 2019-2023 | Octrode |
| Sanofi-Aventis U.S. LLC | $125.33 | 2019-2021 | |
| Exact Sciences Corporation | $104.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $99.77 | 2023-2024 | Auvelity |
| Horizon Therapeutics Plc | $91.75 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $82.05 | 2021 | |
| Lundbeck LLC | $80.52 | 2024-2025 | Rexulti |
| Eisai INC. | $78.93 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $70.03 | 2022-2024 | Quviviq |
| Corium, LLC | $59.04 | 2022-2023 | Azstarys |
| Shield Therapeutics INC | $54.83 | 2022-2023 | Accrufer |
| Supernus Pharmaceuticals, INC. | $53.68 | 2023-2024 | Qelbree, Qelbree |
| Genentech USA, INC. | $52.88 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $51.00 | 2019 | |
| Shire North American Group INC | $47.60 | 2019 | |
| Nevro Corp. | $45.66 | 2022-2023 | Senza |
| Novartis Pharmaceuticals Corporation | $44.74 | 2022 | |
| Atland Pharmaceuticals, LLC | $39.94 | 2024 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Currax Pharmaceuticals LLC | $38.41 | 2021-2022 | |
| Bausch Health US, LLC | $34.82 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.09 | 2022 | |
| Vistapharm, INC. | $26.66 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.98 | 2023 | Edarbi |
| Gilead Sciences, INC. | $17.99 | 2020 | |
| Alfasigma USA, INC. | $14.61 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $14.37 | 2019 | |
| Dexcom, INC. | $13.58 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.30 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Beth Harr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.